Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications

Document Type

Article

Publication Date

2-28-2012

Abstract

The design and feasibility of a simple process of incorporating stable nanoparticles into edible polymer films is demonstrated with the goal of enhancing the dissolution rate of poorly water soluble drugs. Nanosuspensions produced from wet stirred media milling (WSMM) were transformed into polymer films containing drug nanoparticles by mixing with a low molecular weight hydroxylpropyl methyl cellulose (HPMC E15LV) solution containing glycerin followed by film casting and drying. Three different BCS Class II drugs, naproxen (NPX), fenofibrate (FNB) and griseofulvin (GF) were studied. The influence of the drug molecule on the film properties was also investigated. It was shown that film processing methodology employed has no effect on the drug crystallinity according to X-ray diffraction (XRD) and Raman spectroscopy. Differences in aggregation behavior of APIs in films were observed through SEM and NIR chemical imaging analysis. NPX exhibited the strongest aggregation compared to the other drugs. The aggregation had a direct effect on drug content uniformity in the film. Mechanical properties of the film were also affected depending on the drug-polymer interaction. Due to strong hydrogen bonding with the polymer, NPX exhibited an increase in Young's Modulus (YM) of approximately 200%, among other mechanical properties, compared to GF films. A synergistic effect between surfactant/polymer and drug/polymer interactions in the FNB film resulted in an increase of more than 600% in YM compared to the GF film. The enhancement in drug dissolution rate of films due to the large surface area and smaller drug particle size was also demonstrated. © 2011 Elsevier B.V. All rights reserved.

Identifier

84856537441 (Scopus)

Publication Title

International Journal of Pharmaceutics

External Full Text Location

https://doi.org/10.1016/j.ijpharm.2011.12.001

e-ISSN

18733476

ISSN

03785173

PubMed ID

22178619

First Page

496

Last Page

508

Issue

2

Volume

423

Grant

EEC-0540855

Fund Ref

European Research Council

This document is currently not available here.

Share

COinS